Literature DB >> 34094662

Background, applications and challenges of radiogenomics in genitourinary tumor.

Longfei Liu1, Xiaoping Yi2, Can Lu3, Yingxian Pang1, Xiongbing Zu1, Minfeng Chen1, Xiao Guan1.   

Abstract

Genitourinary tumors are groups of tumors with high complexity and heterogeneity. For long-term monitoring, biomarkers that can be used in detection, grading and treatment response assessment are needed. With rapid development in imaging technology and cancer genomics, radiogenomics, the combination of "radiology" and "genomics", has emerged as a powerful tool in oncology practice in recent years because imaging can provide some information that genomic test cannot as gene expression and mutation status are usually evaluated on a small portion of the tumor and are usually not powerful enough to reflect tumor heterogeneity. Radiogenomics investigates the correlations between imaging features and gene expression of a disease, especially in oncologic diseases. It aims to detect the disease's mutation status and supplement genomic analysis based on imaging analysis, providing additional findings for diagnosis, treatment decisions, evaluation of treatment response and prognosis prediction of the disease. Recent years have seen an increase in the number of studies investigating the application of radiogenomics in genitourinary tumors. Many studies have shown promising results. However, there still exist limitations and challenges. In this review, we will summarize recent applications of radiogenomics in genitourinary tumors and discuss limitiations, challenges and future directions of radiogenomics. AJCR
Copyright © 2021.

Entities:  

Keywords:  Genitourinary tumors; gene mutation; mutation status; radiogenomics

Year:  2021        PMID: 34094662      PMCID: PMC8167692     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  54 in total

1.  Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.

Authors:  Christoph A Karlo; Pier Luigi Di Paolo; Joshua Chaim; A Ari Hakimi; Irina Ostrovnaya; Paul Russo; Hedvig Hricak; Robert Motzer; James J Hsieh; Oguz Akin
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

2.  MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.

Authors:  Banumathy Gowrishankar; Ilsiya Ibragimova; Yan Zhou; Michael J Slifker; Karthik Devarajan; Tahseen Al-Saleem; Robert G Uzzo; Paul Cairns
Journal:  Cancer Biol Ther       Date:  2013-12-18       Impact factor: 4.742

3.  A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma.

Authors:  Peng Lin; Dong-Yue Wen; Ling Chen; Xin Li; Sheng-Hua Li; Hai-Biao Yan; Rong-Quan He; Gang Chen; Yun He; Hong Yang
Journal:  Eur Radiol       Date:  2019-08-08       Impact factor: 5.315

4.  Machine learning-based unenhanced CT texture analysis for predicting BAP1 mutation status of clear cell renal cell carcinomas.

Authors:  Burak Kocak; Emine Sebnem Durmaz; Ozlem Korkmaz Kaya; Ozgur Kilickesmez
Journal:  Acta Radiol       Date:  2019-10-21       Impact factor: 1.990

5.  Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.

Authors:  Peter J Hoskin; Ana M Rojas; Søren M Bentzen; Michele I Saunders
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

6.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

7.  The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma.

Authors:  Neema Jamshidi; Eric Jonasch; Matthew Zapala; Ronald L Korn; Lejla Aganovic; Hongjuan Zhao; Raviprakash Tumkur Sitaram; Robert J Tibshirani; Sudeep Banerjee; James D Brooks; Borje Ljungberg; Michael D Kuo
Journal:  Radiology       Date:  2015-08-19       Impact factor: 11.105

8.  The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial.

Authors:  Neema Jamshidi; Eric Jonasch; Matthew Zapala; Ronald L Korn; James D Brooks; Borje Ljungberg; Michael D Kuo
Journal:  Eur Radiol       Date:  2015-11-11       Impact factor: 5.315

9.  Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations.

Authors:  Peter J Hoskin; Dawn M Carnell; N Jane Taylor; Rowena E Smith; J James Stirling; Frances M Daley; Michele I Saunders; Søren M Bentzen; David J Collins; James A d'Arcy; Anwar P Padhani
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-07-15       Impact factor: 7.038

Review 10.  Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.

Authors:  Bum Jun Kim; Jung Han Kim; Hyeong Su Kim; Dae Young Zang
Journal:  Oncotarget       Date:  2017-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.